High Risk and Advanced Upper Tract Urothelial Carcinoma – Still a Role for Surgery
Jennifer A. Linehan, MD explores the treatment of advanced upper tract urothelial carcinoma (UTUC), focusing on therapeutic strategies.
Read MoreSelect Page
Jennifer A. Linehan, MD, is a board-certified urologist and associate professor of urology and urologic oncology at the Saint John’s Cancer Institute in Santa Monica, California. She completed her medical degree as well as a general surgery internship and urology residency at the University of Arizona, where she also received the George M. Drach Award for the most compassionate urologic resident. She also received awards for research in diagnosis and management of kidney cancer. Most recently, she received the Harold H. Benjamin Innovation Award for compassion and dedication in cancer care. After her residency at the University of Arizona, Dr. Linehan completed a two-year fellowship in robotic urologic oncology at City of Hope.
Dr. Linehan’s current research focus is on molecular testing using miRNA and cfDNA in urine for tumor identification in renal tumors, 3D imaging to improve surgical outcomes, and new intracavitary therapy for urothelial carcinoma. She continues to practice general urology including complex robotic reconstruction, voiding dysfunction, and treatment of nephrolithiasis. In addition, Dr. Linehan has been involved in prostate cancer research and biomarker identification for this disease. She has authored papers, presented abstracts and research at conferences around the world, and continues to dedicate time to both science and clinical research. Dr. Linehan is certified by the American Board of Urology and is a member of the Society of Urologic Oncology, Endourological Society, American Urological Association, and the Western Section of the American Urological Association. She also has a lifelong love of animals, particularly rescue dogs. She dedicates time weekly to help educate less fortunate families and children.
Dr. Linehan has the following disclosures:
UroGen: Site Principal Investigator, OLYMPUS Trial; Scientific Advisory Board
Posted by Jennifer A. Linehan, MD | Dec 2022
Jennifer A. Linehan, MD explores the treatment of advanced upper tract urothelial carcinoma (UTUC), focusing on therapeutic strategies.
Read MorePosted by Jennifer A. Linehan, MD | Dec 2022
Jennifer A. Linehan, MD, discusses molecular characterization in invasive bladder cancer, molecular profiling, FGFR3 mutations and FGFR inhibitors.
Read MorePosted by Jennifer A. Linehan, MD | Oct 2019
Jennifer A. Linehan, MD, surveys the current landscape of treatment for upper tract urothelial cancer (UTUC), difficulties with current methods, and promising future treatment options, including kidney-sparing options for low-grade disease. She details the current European Association of Urology (EAU) prognostic algorithm and National Comprehensive Cancer Network (NCCN) guidelines, and discusses the benefits and risks of the “watchful waiting” method of disease management as well as updated approaches to treatment algorithms for UTUC.
Read More